A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer
A Naeim, PR Ward, HJ Wang, R Dichmann… - Journal Of Geriatric …, 2013 - Elsevier
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …
First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial
J Feliu, A Salut, M Safont, F Losa, C Garcia… - Journal of Clinical …, 2008 - ascopubs.org
15120 Background: Elderly pts with metastatic colorectal cancer (mCRC) are frequently
treated with Capecitabine (Cap) alone if they present comorbidities that make them …
treated with Capecitabine (Cap) alone if they present comorbidities that make them …
The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
M Ozcelik, H Odabas, O Ercelep, S Yuksel… - Clinical and …, 2016 - Springer
Aim The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is
complicated by a lack of general agreement. The aim of this study was to evaluate the …
complicated by a lack of general agreement. The aim of this study was to evaluate the …
Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic …
510 Background: In an aging population a greater proportion of geriatric patients will be
considered for systemic chemotherapy. CRC is a common cancer and will be a major health …
considered for systemic chemotherapy. CRC is a common cancer and will be a major health …
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
A Puthillath, T Mashtare Jr, G Wilding… - Critical reviews in …, 2009 - Elsevier
PURPOSE: This phase II study was conducted to determine the efficacy and safety of
capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients …
capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients …
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of …
MP Saunders, I Lang, E Marcuello, V Lorusso, J Ocvirk… - 2013 - ascopubs.org
3521 Background: Elderly patients (pts) are underrepresented in clinical trials. The open-
label phase III trial AVEX evaluated the benefit of adding bevacizumab (BEV) to …
label phase III trial AVEX evaluated the benefit of adding bevacizumab (BEV) to …
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
J Feliu, MJ Safont, A Salud, F Losa… - British journal of …, 2010 - nature.com
Background: The efficacy and safety of capecitabine and bevacizumab in elderly patients
with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line …
with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line …
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label …
D Cunningham, I Lang, E Marcuello, V Lorusso… - The lancet …, 2013 - thelancet.com
Background Elderly patients are often under-represented in clinical trials of metastatic
colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus …
colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus …
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal …
Y Munemoto, M Kanda, K Ishibashi, T Hata… - BMC cancer, 2015 - Springer
Background Although number of elderly patients with metastatic colorectal cancer (mCRC)
is rapidly increasing, this population is often underrepresented in clinical trials. Recently, a …
is rapidly increasing, this population is often underrepresented in clinical trials. Recently, a …
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
E Vrdoljak, T Omrcen, M Boban, A Hrabar - Anti-cancer drugs, 2011 - journals.lww.com
The relative survival of elderly patients with metastatic colorectal cancer (mCRC) is
generally worse than that of younger patients because of more advanced stage at …
generally worse than that of younger patients because of more advanced stage at …
相关搜索
- elderly patients performance status
- poor performance status
- safety of capecitabine bevacizumab combination
- capecitabine cape bevacizumab bev
- open label capecitabine alone
- safety of capecitabine cancer patients
- elderly patients capecitabine and bevacizumab
- elderly patients bevacizumab bev
- cancer patients bevacizumab combination
- elderly patients open label
- elderly patients biweekly capecitabine
- elderly patients capecitabine cape
- elderly patients capecitabine alone
- elderly patients combination with capecitabine
- elderly patients bevacizumab in combination
- cancer patients efficacy and safety